REG - Verici Dx PLC - Notice of AGM and posting of Annual Report

Verici DxAnnouncement

31/05/2024 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240531:nRSe6994Qa&default-theme=true

RNS Number : 6994Q  Verici Dx PLC  31 May 2024

Verici Dx plc

("Verici Dx" or the "Company")

 

Posting of Annual Report & Accounts

and

Notice of Annual General Meeting

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, confirms that the Annual Report and Accounts for the year
ended 31 December 2023 ("2023 Annual Report") and the Notice of the 2024
Annual General Meeting ("AGM") have now been published on the Company's
website vericidx.com/investors/ (https://vericidx.com/investors/) .

 

The 2023 Annual Report, the Notice of AGM and details for voting by
proxy will be posted to shareholders who have not consented to receive
electronic communications today, on 31 May 2024.

 

The AGM is to be held on 25 June 2024 at 11.30 a.m. at Shoosmiths LLP, No. 1
Bow Churchyard, London EC4M 9DQ and will consider the Resolutions set out in
the Notice of AGM.

 

Proxy voting

Shareholders will not receive a hard copy form of proxy for the AGM in the
post. Instead, shareholders will be able to vote electronically using the
link www.signalshares.com (http://www.signalshares.com/) . Proxy votes must
be received no later than 11.30 a.m. on 21 June 2024.

 

Shareholders may request a hard copy form of proxy directly from the
Registrars, Link Group, on Tel: 0371 664 0300. Calls are charged at the
standard geographic rate and will vary by provider. Calls outside the United
Kingdom will be charged at the applicable international rate. Lines are open
between 09:00 - 17:30, Monday to Friday excluding public holidays in England
and Wales. Alternatively, shareholders can vote by downloading the new app,
LinkVote+, on Apple App Store or Google Play and following the instructions.

 

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     investors@vericidx.com
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: +44 20 7496 3000
 Aubrey Powell / Sam Butcher

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOALFLFXZELEBBZ